Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics
MYOV Stock Summary
- Myovant Sciences Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.74% of US listed stocks.
- MYOV's price/sales ratio is 49.8; that's higher than the P/S ratio of 94.5% of US stocks.
- MYOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.16% of US stocks.
- If you're looking for stocks that are quantitatively similar to Myovant Sciences Ltd, a group of peers worth examining would be CDXS, BCYC, KPTI, BLDP, and SILC.
- Visit MYOV's SEC page to see the company's official filings. To visit the company's web site, go to myovant.com.
MYOV Stock Price Chart Interactive Chart >
MYOV Price/Volume Stats
|Current price||$19.48||52-week high||$30.90|
|Prev. close||$19.04||52-week low||$11.04|
|Day high||$19.64||Avg. volume||955,589|
|50-day MA||$21.39||Dividend yield||N/A|
|200-day MA||$20.11||Market Cap||1.77B|
Myovant Sciences Ltd. Common Shares (MYOV) Company Bio
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.
MYOV Latest News Stream
|Loading, please wait...|
MYOV Latest Social Stream
View Full MYOV Social Stream
Latest MYOV News From Around the Web
Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 yearsContraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 ...
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in EuropeRelugolix is FDA-approved and currently available in the U.S. under the trade name ORGOVYX™ Pfizer has an exclusive option to commercialize relugolix in oncology outside of the U.S. and Canada, excluding certain Asian countries, with a decision expected in the first half of 2021 BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer. The validation of the application confirms the submission is suf...
Robert W. Baird Stick to Their Buy Rating for Myovant Sciences
U.S. Uterine Fibroid Treatment Market | Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems
U.S. Uterine Fibroid Treatment Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading
MYOV Price Returns